ENSC — Ensysce Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1716947 ·
Last close
$0.36
Market Cap
$7.02M
52W High
$0.98
52W Low
$0.24
ADV30
29,698,563
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,562,230 | -3,556,415 | 2,167,803 | 745,482 | 2,836,815 |
| Dec 2025 | 0 | — | -2,781,825 | -2,767,648 | 7,452,479 | 4,310,354 | 4,567,729 |
| Sep 2025 | 0 | — | -3,741,095 | -3,729,128 | 3,179,464 | 1,673,218 | 2,304,750 |
| Jun 2025 | 0 | — | -1,750,515 | -1,733,351 | 5,574,455 | 2,211,575 | 2,514,043 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-9,599,805
Investing CF
$0
Financing CF
$7,416,439
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.35
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-143,276,414
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,768,195
Pretax Income TTM
$-11,787,029
Interest Exp TTM
$18,834
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,500,753
EBITDA
—
Free Cash Flow
$-4,498,445
Enterprise Value
$6,454,223
Total Cash
$676,704
Total Debt
$196,842
Shares Out
19,456,794
Trailing EPS
$-2.56
Book Value
$-0.05
ROE
-1295.1%
ROA
-185.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -10,240,946 | -10,175,700 | 7,452,479 | 4,567,729 | — | -7,806,292 |
| Dec 2024 | 0 | -6,730,134 | -7,986,935 | 5,597,232 | 2,217,293 | — | -7,502,700 |
| Dec 2023 | 0 | -10,718,187 | -10,613,074 | 2,708,085 | 3,359,352 | — | -10,779,982 |
| Dec 2022 | 0 | -24,222,095 | -24,172,292 | 5,885,052 | 9,914,704 | — | -17,887,439 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | $7.17M | $4.75 | — |
| CANF | Can-Fite BioPharma Ltd. | $7.18M | $3.35 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $7.20M | $3.74 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.26M | $4.63 | — |
| ALZN | Alzamend Neuro, Inc. | $7.43M | $1.55 | — |
News headlines (Yahoo Finance, 1h cache)
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
2026-08-20 12:00 · Yahoo
ENSC Sets Itself Up Nicely for Critical Stage
2026-08-14 12:12 · Yahoo
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:15 · Yahoo
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing
2026-08-06 14:50 · Yahoo
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development
2026-07-14 14:45 · Yahoo
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
2026-07-14 12:00 · Yahoo
ENSC Receives Vital Funding for Drive to Commercialization
2026-07-14 11:58 · Yahoo
Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics
2026-07-09 14:41 · Yahoo
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
2026-06-26 12:00 · Yahoo
ENSC Advancing Testing and Expanding Potential
2026-05-18 11:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.